Src kinase inhibitor (Walter and Eliza Hall Institute/Ludwig Institute of Medical Research/Centre for Drug Candidate Optimisation)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameSrc kinase inhibitor (Walter and Eliza Hall Institute/Ludwig Institute of Medical Research/Centre for Drug Candidate Optimisation)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase SRC inhibitors
TargetsTyrosine-protein kinase SRC
Therapy Area/IndicationsColonic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New Zealand
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesWalter And Eliza Hall Institute Of Medical Research
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCentre for Drug Candidate OptimisationLudwig Institute For Cancer ResearchWalter And Eliza Hall Institute Of Medical Research
Active IndicationsN/A
Inactive IndicationsColonic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A